AjayR Mhatale’s Post

🧠 A TBR of >2.4 on FDG-PET might indicate impending 𝗵𝘆𝗽𝗼𝗽𝗵𝘆𝘀𝗶𝘁𝗶𝘀 in patients under 𝗶𝗺𝗺𝘂𝗻𝗲-𝗰𝗵𝗲𝗰𝗸𝗽𝗼𝗶𝗻𝘁 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 (ICIs). ▪️ Hypophysitis is a frequent side effect of ICIs, particularly in combination therapies. 💉 ▪️ It is often clinically silent and typically presents only when pituitary hormone deficiencies develop. ▪️ In approximately one-third of patients with ICI-induced hypophysitis, MRI 🧲 may show no abnormalities of the pituitary gland at the time of diagnosis (Di Dalmazi G. et al. Expert Rev Endocrinol Metab. 2019 Nov;14(6):381-398). Recent work by our group published in Clinical Nuclear Medicine #CNM: 👉 https://lnkd.in/dTKiMSh7 Alessa Fischer ¦ Julia M Martínez-Gómez ¦ Joanna Mangana ¦ Reinhard Dummer ¦ Zoran Erlic ¦ Svenja Nölting ¦ FELIX BEUSCHLEIN ¦ Alexander Maurer ¦ Michael Messerli ¦ Stephan Skawran Universitätsspital Zürich #USZ #HybridImaging #NuclearMedicine

 "𝗥𝗮𝗱𝗶𝗮𝘁𝗶𝗻𝗴 𝗚𝗿𝗼𝘄𝘁𝗵: 𝗧𝗵𝗲 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 #𝗡𝘂𝗰𝗹𝗲𝗮𝗿 #𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 " The Nuclear Medicine market is witnessing remarkable growth, valued at $82.78 billion in 2023 and projected to reach $244.02 billion by 2030, with a robust CAGR of 16.7%. 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗡𝘂𝗰𝗹𝗲𝗮𝗿 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲? Nuclear medicine is a specialized branch of radiology that employs small amounts of radioactive materials (radionuclides) for medical research, diagnosis, and treatment, particularly in oncology. Unlike traditional imaging techniques, it provides critical insights into the function of organs and tissues, enabling targeted therapies and improved patient outcomes.  𝗙𝗼𝗿 𝗮 𝘁𝗵𝗼𝗿𝗼𝘂𝗴𝗵 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴, 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝘀𝘁𝘂𝗱𝘆 𝘃𝗶𝗮 𝘁𝗵𝗶𝘀 𝗹𝗶𝗻𝗸:https://lnkd.in/gaKerEeP Key Players Driving Innovation: GE HealthCare Siemens Healthineers Philips Cardinal Health Bayer | Pharmaceuticals Technological Advancements: GE Healthcare's StarGuide and NM/CT 870 CZT systems leverage advanced Cadmium Zinc Telluride (CZT) technology for superior imaging capabilities. PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) continue to revolutionize diagnostic imaging, offering three-dimensional insights into various diseases, including cancer and cardiovascular conditions. Market Dynamics: Drivers: The increasing incidence of cancer and cardiovascular diseases, with 20 million new cancer cases reported in 2022. Technological advancements enhancing diagnostic accuracy and treatment efficacy. Market Segmentation: - Oncology: Leading application, emphasizing targeted therapies for cancer treatment. - Cardiovascular: Growing relevance due to the rising prevalence of cardiovascular diseases. Future Outlook: The Nuclear Medicine market is poised for substantial development, driven by rising disease prevalence and ongoing technological innovations. The WHO projects over 35 million new cancer cases by 2050, marking a 77% increase from 2022 estimates. Recent Developments: Strategic partnerships and acquisitions, such as between Lantheus Holdings and Perspective Therapeutics, are enhancing treatment options, especially for neuroendocrine tumors, while major players like Bayer AG expand their capabilities in targeted imaging and therapeutic radiopharmaceuticals. As we look ahead, the advancements in nuclear medicine offer a promising future for patient care and treatment efficacy. Let's connect to discuss how these innovations are shaping the healthcare landscape! #NuclearMedicine #HealthcareInnovation #Radiology #Oncology #CardiovascularHealth #MarketTrends #HealthTech

𝗨.𝗦. 𝗡𝘂𝗰𝗹𝗲𝗮𝗿 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟭. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The U.S. nuclear medicine market was valued at USD 5.1 billion in 2024 and is anticipated to grow at a CAGR of 12.6% until 2030, driven primarily by the increasing prevalence of cancer and cardiovascular diseases. According to the American Cancer Society, there were approximately 1,958,310 new cancer cases and 609,820 cancer-related deaths in the U.S. in 2023. The market is further buoyed by technological advancements in nuclear medicine and the growing need for precise diagnostic and treatment options. The diagnostic centers segment, in particular, is expected to see notable growth due to the escalating number of nuclear medicine diagnostic procedures, underscored by National Cancer Institute data showing nearly 2 million cancer diagnoses in 2024. This surge in chronic disease incidence is set to enhance diagnosis rates and propel market expansion throughout the forecast period. 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝗰𝗼𝗽𝗲 𝗮𝗻𝗱 𝗗𝗲𝗺𝗮𝗻𝗱 𝗼𝗳 𝗨.𝗦. 𝗡𝘂𝗰𝗹𝗲𝗮𝗿 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗠𝗮𝗿𝗸𝗲𝘁. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/e5CVR7-x *𝗕𝘆 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀: Diagnostic Products, Therapeutic Products, *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Cardiology, Neurology, Oncology, Thyroid, Lymphoma, Bone Metastasis, Therapeutic Applications, Endocrine Tumor, Pulmonary Scans, Others *𝗕𝘆 𝗘𝗻𝗱-𝗨𝘀𝗲: Hospitals & Clinics, Diagnostic Centers, Others *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Eckert & Ziegler SE, Curium Pharma, GE HealthCare, Bracco Imaging do Brasil, Nordion, NTP Radioisotopes, Eczacıbaşı-Monrol Nuclear Products, Novartis, Siemens Healthineers #nuclearmedicine #radiology #medicalimaging #radiopharmaceuticals #petct #diagnosticimaging #radiationtherapy #healthcare #oncology #radiologists #medicine #medicaltechnology #cancertreatment #imaging #nuclearmed #theranostics #radiotracer #hospital #healthcareinnovation #cancerdiagnosis #clinicalresearch #molecularimaging #radiopharmacy #radiationoncology #imagingtechnology #healthtech #medicalresearch #nuclearmedtech #nuclearmedicinephysician #radiationsafety

🌟 Understanding the Gallium Scan in Nuclear Medicine 🌟 A gallium scan is a crucial diagnostic tool in nuclear medicine, bridging clinical expertise with advanced imaging technology to detect various infections, inflammation, and certain types of cancers. Here’s a closer look from both the medical and technical perspectives: Medical Perspective 🏥 Gallium scans play a vital role in detecting conditions like lymphoma, sarcoidosis, and certain types of lung infections. By binding to transferrin, a protein in the blood, gallium-67 helps visualize areas with abnormal cellular activity. This makes it valuable for: • Cancer Diagnosis and Staging: Especially helpful in lymphomas, it assists in pinpointing tumor locations and monitoring response to therapy. • Infection and Inflammation: Gallium scans help identify sites of infection, especially in immunocompromised patients, by detecting inflammation. • Whole-Body Imaging: It provides a full-body scan, allowing for comprehensive assessment of multiple sites in one go, which is invaluable in cases where the disease could be systemic. Technical Perspective ⚙️ The technology behind gallium scans combines radioactive isotopes with advanced imaging devices to produce clear, detailed pictures. Key technical aspects include: • Isotope Selection: Gallium-67, a gamma-emitting isotope, is used because of its half-life, which suits imaging over several days. It allows adequate time for the isotope to accumulate in target areas. • Imaging Procedure: Gallium-67 is injected into the patient, and images are captured using a gamma camera over a period (often 24-72 hours) to observe how gallium distributes in the body. • Gamma Camera Technology: Using single-photon emission computed tomography (SPECT), the gamma camera rotates around the patient, providing 3D images that offer more precision in locating abnormal tissues. • Challenges and Considerations: While powerful, gallium scans require consideration of isotope half-life, patient preparation, and timing of imaging to ensure diagnostic accuracy. 💡 In Summary: Gallium scans represent the synergy of medicine and technology, offering clinicians insights that guide diagnosis and treatment strategies for complex diseases. #NuclearMedicine #GalliumScan #MedicalImaging #Diagnostics #HealthcareInnovation #ImagingTechnology

📃Scientific paper: Diagnostics and Theranostics of Benign Thyroid Disorders Abstract: Thyroid scintigraphy is an evergreen in nuclear medicine imaging and up to date represents the only “in vivo” diagnostic imaging method able to evaluate thyroid functional status in patients with thyroid disorders. It is able to identify hyperfunctioning (i.e., “hot”) or hypofunctioning (i.e., “cold”) nodules such as an increased tracer uptake in the whole gland common in patients affected by autoimmune thyroid disorders (i.e., Graves’ disease). Most hyperthyroid patients and selected patients affected by non-toxic thyroid disorders can be successfully cured using iodine-131, the first theragnostic agent in nuclear medicine. Indeed, it is able to treat thyroid disorder by β decay while γ-emission allows us to observe its distribution in the gland. Millions of people have worldwide been treated by iodine-131 since its first use by Dr. Saul Hertz in a young female patient affected by Graves’ disease. Being an effective and safe therapy, iodine-131 therapy is now considered as a therapeutic option both in selected pediatric patients such as in those affected by non-toxic goiter. In these latter, its use is more common than in the past. The present chapter is prompted to provide the readers with an updated overview on diagnostic and theragnostic approach to patients affected by benign thyroid disorders. Continued on ES/IODE ➡️ https://etcse.fr/OMGR ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Diagnostics and Theranostics of Benign Thyroid Disorders Abstract: Thyroid scintigraphy is an evergreen in nuclear medicine imaging and up to date represents the only “in vivo” diagnostic imaging method able to evaluate thyroid functional status in patients with thyroid disorders. It is able to identify hyperfunctioning (i.e., “hot”) or hypofunctioning (i.e., “cold”) nodules such as an increased tracer uptake in the whole gland common in patients affected by autoimmune thyroid disorders (i.e., Graves’ disease). Most hyperthyroid patients and selected patients affected by non-toxic thyroid disorders can be successfully cured using iodine-131, the first theragnostic agent in nuclear medicine. Indeed, it is able to treat thyroid disorder by β decay while γ-emission allows us to observe its distribution in the gland. Millions of people have worldwide been treated by iodine-131 since its first use by Dr. Saul Hertz in a young female patient affected by Graves’ disease. Being an effective and safe therapy, iodine-131 therapy is now considered as a therapeutic option both in selected pediatric patients such as in those affected by non-toxic goiter. In these latter, its use is more common than in the past. The present chapter is prompted to provide the readers with an updated overview on diagnostic and theragnostic approach to patients affected by benign thyroid disorders. Continued on ES/IODE ➡️ https://etcse.fr/OMGR ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Are you participating in the #theranostics business ecosystem? In what ways? As my second article of the Rise of Theranostics series posts today, I thank University of Texas Health San Antonio's Department of Radiology, Penny Vroman, MD, and the nuclear medicine technologists at MARC for sharing their center's work with AuntMinnie.com first. https://lnkd.in/eu5rpkxu

PanMediso Spotlight｜Classification and Application of Medical Radioisotopes (II) Radioisotope therapy is a method of treating diseases using rays emitted by decaying radioisotopes. By selectively delivering radioisotopes to diseased tissues or cells, precise irradiation and destruction of diseased cells, and minimizing the effect on normal tissues can be achieved. Radioisotopes for Treatment. (1) emit only a-particles, beta-particles, Roche electrons, or are accompanied by the emission of only a small amount of weak gamma-rays. (2) Half-life from several hours to tens of days. (3) Radioactive agents with high specific activity can be obtained thereby. The therapeutic radioisotope Ac-225 with ideal half-life of 9.9d and high lethality of alpha rays, as well as the nuclear drug validity period of up to 120 hours, has a good therapeutic potential in the treatment of systemic micro-tumor foci, such as pancreatic cancer, prostate cancer, neuroendocrine tumors, and leukemias. As an international company dedicated to the ecosystem building of nuclear medicine, PanMediso Holdings provides GMP-grade production and global supply of new isotopes, in particular Ge-68 for diagnosis and Ac-225 for treatment, thereby bringing new power to the development of human health. #Ac225 #Radioisotope #68Ga #Radiotherapy

First-in-human hyperPET: simultaneous hyperpolarized 13C-pyruvate MRS and 18F-FDG-PET in a patient with lymphoma We are proud to announce the publication of the first hyperPET performed in a cancer patient. Hyperpolarized 1-13C-pyruvate magnetic resonance spectroscopy (MRS) and MRS imaging (MRSI) offer noninvasive and real-time direct assessment of the altered metabolism of cancer cells known as the Warburg effect. When combined with simultaneously acquired 18F-FDG PET in a PET/MR scanner, coined hyperPET by us, this dual-modality may unveil cancer-type specific glucose metabolic phenotypes with potential implications for patient prognostication, treatment response assessment, and prediction. Now, we present the first human data of simultaneously acquired hyperpolarized MRS/MRSI and PET performed in a PET/MR scanner, as well as the first human hyperpolarized MRS/MRSI data from a patient with lymphoma. Congratulations to Mathias H., Andreas Clemmensen, Emil Christensen, Charlotte Denholt, Helle Hjorth Johannesen, Nic Gillings, Esben Andreas Carlsen, Malene Martini Clausen, Martin Hutchings, Thomas Lund Andersen, Jan Henrik Ardenkjaer-Larsen, and Andreas Kjaer The article, published in Clinical Nuclear Medicine, can be found here: https://lnkd.in/dtMkvbm6 Rigshospitalet Københavns Universitet - University of Copenhagen #hyperpet #hyperpolarized #MRS #PETMR #FDG

PanMediso Spotlight｜Classification and Application of Medical Radioisotopes (I) Medical radioisotopes play a vital role in modern medicine. They are widely used in the diagnosis and treatment of diseases, based on the type of rays, their sources and the diversity of clinical applications. Classification of medical radioisotopes Medical radioisotopes can be categorized in the following three dimensions: Types of rays: alpha isotopes, beta isotopes, gamma isotopes. Source: reactor prepared isotopes, gas pedal prepared isotopes, spent fuel extracted isotopes. Clinical uses: diagnostic isotopes, therapeutic isotopes. Diagnostic Isotopes Diagnostic radioisotopes are classified into three categories: function measurement, imaging and analysis. Since it is rapid, simple and painless as an examination method, it is easily accepted by patients and has been widely used in tumor diagnosis. Diagnostic radioisotopes are applied in SPECT, PET technology and its molecular imaging technology integrated with CT and MR, which have unique advantages in the precise diagnosis, staging, therapeutic efficacy evaluation and prognosis assessment of tumors. Application Value of 68Ga 68Ga, produced by the 68Ge-68Ga generator, is a radiotracer for PET, capable of labeling a wide range of biomolecules, and is widely used in tumor imaging, diagnosis of neurodegenerative diseases, and evaluation of cardiovascular diseases. 68Ga is one of the more widely used positronuclides in PET/CT, and is only second in frequency to 18F, with outstanding scientific research value and clinical significance. It has outstanding scientific research value and clinical significance. As an international company dedicated to the ecosystem building of nuclear medicine, PanMediso Holdings provides GMP-grade production and global supply of new isotopes, in particular Ge-68 and Ac-225. Asscientific research and innovation evolves, medical isotopes will further enhance the accuracy of medical imaging. #SPECT #PET #18F #Radioisotopes #68Ga #Ac225